Required Reading:
Eon van der M. S. & Bredenkamp J. (2013). Originator and generic medicine: Pricing and market share. International Journal of Pharmaceutical and Healthcare Marketing 7(2) 104-119.
Gandjour A. (2013). Reference pricing and price negotiations for innovative new drugs: Viable policies in the long term? PharmacoEconomics 31(1) 11-4.
Jones J.D. (2003). Developing an effective generic prescription drug program. Benefits Quarterly 19(1): 14-18.
Kal Z. Annemans L. & Garrison L. P. (2013). Differential pricing of new pharmaceuticals in lower income European countries. Expert Review of Pharmacoeconomics & Outcomes Research 13(6) 735-41.
Kramer D. B. & Kesselheim Aaron S. (2013). The medical device excise tax over before it begins? The New England Journal of Medicine 368(19) 1767-9.
Monasterio E. & Gleeson D. (2014). Pharmaceutical industry behaviour and the trans pacific partnership agreement. The New Zealand Medical Journal (Online) 127(1389) 6-12.
Sorenson C. Drummond M. & Burns L. R. (2013). Evolving reimbursement and pricing policies for devices in europe and the united states should encourage greater value. Health Affairs 32(4) 788-96.
Sussex J. Towse A. & Devlin N. (2013). Operationalizing value-based pricing of medicines: A taxonomy of approaches. PharmacoEconomics 31(1) 1-10.
Wu J. Xu J. Liu G. & Wu J. (2014). Pharmaceutical pricing: An empirical study of market competition in Chinese hospitals. PharmacoEconomics 32(3) 293-303.
1. Describe a Banner University of Arizona Medical Center (Tucson Arizona) pricing strategy for one of its services or products (e.g. a pharmaceutical drug or a medical device).
2. Explain how costs would be taken into account when formulating that pricing strategy.

Is this the question you were looking for? Place your Order Here